ICU Medical, Inc. — Q1 2020 Form 10-Q
Reporting period: Three months ended March 31, 2020; unaudited. ICU Medical develops, manufactures and sells infusion therapy, IV solutions and critical-care products globally.
Financial performance
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| Revenue | $328.6 million | $330.9 million | Down 0.7% |
| Gross profit / margin | $121.4 million / 36.9% | $135.3 million / 40.9% | Margin down 4.0 percentage points |
| Income from operations | $26.1 million | $30.4 million | Down 14.2% |
| Net income | $16.8 million | $31.0 million | Down 45.7% |
| Diluted EPS | $0.78 | $1.44 | Down 45.8% |
| Operating cash flow | $39.5 million | $(21.0) million | Improved $60.5 million |
Revenue by product line: Infusion Consumables $123.5 million, up 2.5%; Infusion Systems $88.4 million, up 4.9%; IV Solutions $104.3 million, down 7.9%; and Critical Care $12.4 million, down 3.9%. International revenue rose to $98.4 million from $83.7 million, while U.S. revenue declined to $230.2 million from $247.2 million.
Gross margin pressure reflected lower IV Solutions manufacturing volumes and charges for disposal of certain infusion sets. Operating expenses were $95.4 million versus $104.9 million. Restructuring, strategic transaction and integration costs totaled $12.3 million, compared with $24.4 million in the prior-year quarter. Other expense was $5.5 million, primarily reflecting $6.1 million in foreign-exchange losses. The effective tax rate was 17%, compared with 7%; the prior-year rate benefited from a $5.6 million discrete tax benefit.
Financial position and liquidity
- Cash, cash equivalents and short-term investments totaled $439.7 million at March 31, up from $292.6 million at year-end 2019.
- Cash and cash equivalents were $419.6 million. Current assets were $1.00 billion and current liabilities were $357.3 million.
- The company borrowed $150.0 million under its revolving credit facility in March as a precaution amid COVID-19 uncertainty. The facility was fully drawn, with no remaining availability; it matures in November 2022. The company reported compliance with its financial covenants.
- Net cash provided by operating activities was $39.5 million; capital expenditures were $25.5 million. Investing activities used $23.5 million and financing activities provided $138.4 million.
- Management estimated 2020 capital expenditures of approximately $85 million to $90 million and said existing cash and expected operating cash flows should fund operations for the next 12 months.
Material changes, outlook and risks
- COVID-19 drove increased customer stocking and demand, particularly for IV Solutions and Infusion Systems, but management warned that stocking could reduce future demand. The pandemic also disrupted operations, restricted customer access and delayed implementations; its future financial impact could not be reasonably estimated.
- Potential impacts cited include manufacturing or supply-chain disruption, changes in hospital demand and elective procedures, customer payment difficulties, added labor costs, currency volatility, delayed cost-saving initiatives and higher interest expense.
- Infusion Systems and Infusion Consumables growth was attributed partly to pandemic-related orders; IV Solutions declined mainly because of lower contract manufacturing sales to Pfizer. Critical Care faced supply constraints.
- There was no specific earnings or revenue guidance. Management’s stated outlook included expected 2020 capital expenditures of $85 million to $90 million and sufficient liquidity for the next 12 months, subject to business conditions and pandemic uncertainty.
- Q1 restructuring charges were $7.2 million, primarily for severance and facility closures; management expected to pay unpaid restructuring charges by year-end. Integration costs included IT-system migration at the Austin facility.
- A federal antitrust case concerning IV saline pricing was dismissed with prejudice on April 3, 2020; plaintiffs could appeal or otherwise challenge the order. The matter involves reciprocal indemnification claims with Pfizer.
- The Pursuit acquisition earn-out liability was $17.3 million, with potential additional consideration of up to $50 million, subject to performance targets. The HIS earn-out was determined not to require a payout.
Important facts for investors to verify
- Whether pandemic-related stocking was temporary and how demand, customer access and product implementations evolved after Q1.
- Whether gross margins recovered from 36.9%, including the effects of IV Solutions volumes and infusion-set disposal charges.
- Cash generation, capital spending and use of the $150 million borrowing, including interest costs and ongoing covenant headroom.
- Exposure to foreign-exchange movements: Q1 included $6.1 million of foreign-exchange losses; the company hedges some Mexican peso exposure but not its euro or Canadian-dollar exposures.
- Resolution or appeal of the saline antitrust litigation and any resulting indemnification exposure; the filing does not quantify a potential liability.